利伐沙班预防肺癌患者发生静脉栓塞的观察

Effect of Rivaroxaban in prevention of venous thromboembolism in Patients with lung cancer

目的观察利伐沙班预防晚期肺癌患者发生静脉血栓栓塞(venous thromboembolism,VTE)的疗效及安全性。方法选择VTE风险评估(Caprini模型)≥5分的20例晚期非小细胞肺癌患者为研究对象,在住院期间进行预防性利伐沙班治疗,分析治疗后VTE发生率、出血风险和各项观察指标与VTE发生率的关系。结果预防性利伐沙班治疗后的VTE发生率为1 0.0%(2/2 0),治疗前D-二聚体升高的患者VTE发生率明显高于D-二聚体正常的患者,差异有统计学意义(P<0.0 5),其余各项观察指标与VTE发生率比较,差异均无统计学意义(P>0.05),全组病例未出现与利伐沙班相关的不良反应。结论利伐沙班可在一定程度上减少晚期肺癌患者VTE的发生率,药物安全可靠。

Objective To explore the effect and safety of Rivaroxaban in preventing terminal non-small lung cancer patients from venous thromboembolism（VTE）. Methods Twenty terminal non-small lung cancer patients evaluated as very high risk grade（≥5） of VTE by Caprini model were chosen as research objects. Prophylactic Rivaroxaban was conducted during the period of hospitalization. The incidence of VTE、risk of bleeding and the relationship between the observation indexes and the incidence of VTE were analyzed. Results After prophylactic Rivaroxaban, the rate of VTE was 10.0%（2/20）. The incidence of VTE in patients with D-dimer rise before treatment was significantly higher than the patients with normal D-dimer（P〈0.05）, There was no significant difference in the incidence of VTE among the other observation indexes（P 〉0.05）. All the cases did not have the Rivaroxaban related adverse reactions.Conclusion Rivaroxaban could reduce the incidence of VTE in advanced lung cancer patients, it was safety and reliable.